The latest announcement is out from I-MAB ( (IMAB) ).
On April 3, 2025, I-Mab announced its financial results for the full year ending December 31, 2024, highlighting significant progress in its pipeline and business operations. The company reported a strong financial position with $173.4 million in cash and investments, supporting its lead program, givastomig, through 2027. I-Mab completed its divestiture of Greater China assets, marking a strategic shift to focus on its U.S. operations. The company is advancing its lead program, givastomig, a promising therapy for gastric cancer, with ongoing Phase 1b trials showing positive momentum. The financial results also showed a reduced net loss from continuing operations, reflecting the company’s strategic realignment and operational efficiencies.
More about I-MAB
I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company has operations in Rockville, Maryland, and Short Hills, New Jersey, and is dedicated to advancing innovative therapies, particularly in the field of immuno-oncology.
YTD Price Performance: -14.51%
Average Trading Volume: 315,569
Technical Sentiment Signal: Strong Buy
Current Market Cap: $60.68M
For an in-depth examination of IMAB stock, go to TipRanks’ Stock Analysis page.